0000902664-17-004371.txt : 20171116
0000902664-17-004371.hdr.sgml : 20171116
20171116114727
ACCESSION NUMBER: 0000902664-17-004371
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171114
FILED AS OF DATE: 20171116
DATE AS OF CHANGE: 20171116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Select Advisor LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 171207268
BUSINESS ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: SUITE 2802
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: SUITE 2802
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
p17-2247form4.xml
IMMUNOMEDICS INC
X0306
4
2017-11-14
0
0000722830
IMMUNOMEDICS INC
IMMU
0001633313
venBio Select Advisor LLC
120 WEST 45TH STREET
SUITE 2802
NEW YORK
NY
10036
1
0
1
1
See Remarks
Common Stock, $0.01 par value per share (the "Common Stock")
2017-11-14
4
P
0
1150000
10.39
A
15889461
I
See footnotes
Common Stock
2017-11-15
4
P
0
175000
10.97
A
16064461
I
See footnotes
The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.2 to $10.8403 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.6584 to $11.3049 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.
The Investment Manager may be deemed a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact that Dr. Agahazadeh currently serves on the board of directors of the Issuer.
venBio Select Advisor LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
2017-11-15
/s/ Behzad Aghazadeh
2017-11-15